MoonLake Immunotherapeutics reports results for the quarter ended March 31 - Earnings Summary

MoonLake Immunotherapeutics

12/05/2025 21:22

MoonLake Immunotherapeutics MLTX.OQ reported a quarterly adjusted loss of 63 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -22 cents.  The mean expectation of thirteen analysts for the quarter was for a loss of 75 cents per share. Wall Street expected results to range from -85 cents to -65 cents per share.

Reported revenue was zero​; analysts expected zero.

MoonLake Immunotherapeutics's reported EPS for the quarter was a loss of 63 cents​.

The company reported a quarterly loss of $39.94 million.

MoonLake Immunotherapeutics shares had fallen by 1.5% this quarter and lost 29.0% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 20.4% in the last three months.​

In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for MoonLake Immunotherapeutics is $74.00

This summary was machine generated from LSEG data May 12 at 08:22 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.75
-0.63
Beat
Dec. 31 2024
-0.60
-0.72
Missed
Sep. 30 2024
-0.44
-0.56
Missed
Jun. 30 2024
-0.28
-0.39
Missed